DarioHealth’s fair value assessment has increased markedly due to a substantial drop in future P/E, outweighing a minor rise in the discount rate, resulting in the consensus analyst price target jumping from $1.96 to $39.25.
What's in the News
- DarioHealth announced a 1-for-20 reverse stock split to be implemented as determined by the Board no later than September 15, 2025.
- Shareholders ratified Kesselman & Kesselman (PwC International Ltd.) as independent auditor for fiscal year ending December 31, 2025.
- DarioHealth and GreenKey Health entered a strategic commercial agreement to deliver integrated behavioral health, sleep, and cardiometabolic care solutions targeting the $150 billion sleep apnea market.
- Four new studies presented at the ADA Scientific Sessions demonstrated DarioHealth’s platform with significant eA1c reduction in GLP-1 users and 89% AI predictive accuracy for future glucose levels, highlighting its competitive strength in digital health and chronic condition management.
Valuation Changes
Summary of Valuation Changes for DarioHealth
- The Consensus Analyst Price Target has significantly risen from $1.96 to $39.25.
- The Future P/E for DarioHealth has significantly fallen from 37.47x to 27.45x.
- The Discount Rate for DarioHealth has risen slightly from 10.99% to 11.26%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.